wilate 1000 powder for solution for i/v injection
octapharma pharmazeutika produktionsges. m.b.h. - human blood coagulation factor viii, human von willebrand factor - powder for solution for i/v injection - 1000iu/10ml+ 1000iu/10ml
octanate 250iu powder and solvent for solution for injection
wellchem pharmaceuticals pte ltd - coagulation factor viii (human) - injection, powder, for solution - 250 iu/5 ml - coagulation factor viii (human) 250 iu/5 ml vial
octanate 500iu powder and solvent for solution for injection
wellchem pharmaceuticals pte ltd - coagulation factor viii (human) - injection, powder, for solution - 500 iu/10 ml - coagulation factor viii (human) 500 iu/10 ml vial
koate-dvi for injection 1000 iu10 ml
grifols asia pacific pte. ltd. - antihemophilic factor (human) (factor viii) - injection, powder, for solution - min 800 iu/10 ml - antihemophilic factor (human) (factor viii) min 800 iu/10 ml
koate-dvi for injection 250 iu5 ml
grifols asia pacific pte. ltd. - antihemophilic factor (human) (factor viii) - injection, powder, for solution - min 250 iu/5 ml - antihemophilic factor (human) (factor viii) min 250 iu/5 ml
koate-dvi for injection 500 iu5 ml
grifols asia pacific pte. ltd. - antihemophilic factor (human) (factor viii) - injection, powder, for solution - min 400 iu/5 ml - antihemophilic factor (human) (factor viii) min 400 iu/5 ml
wilate - von willebrand factor/coagulation factor viii complex (human) (von willebrand factor/coagulation factor viii complex- h
octapharma usa inc - antihemophilic factor human (unii: 839moz74gk) (antihemophilic factor human - unii:839moz74gk), von willebrand factor human (unii: ze22ne22f1) (von willebrand factor human - unii:ze22ne22f1) - antihemophilic factor human 100 [iu] in 1 ml - wilate is indicated in children and adults with von willebrand disease for: - on-demand treatment and control of bleeding episodes - perioperative management of bleeding wilate is indicated in adolescents and adults with hemophilia a for: - routine prophylaxis to reduce the frequency of bleeding episodes - on-demand treatment and control of bleeding episodes wilate is contraindicated in patients with known hypersensitivity reactions, including anaphylactic or severe systemic reactions, to human plasma-derived products, any ingredient in the formulation [see description (11) ] , or components of the container. risk summary there are no data with wilate use in pregnant women to inform a drug-associated risk. animal reproduction studies have not been conducted with wilate. wilate was given to four subjects (3 type 3 and 1 type 2b) during labor and delivery in one clinical study. two subjects underwent vaginal delivery (type 3) and two subjects had a cesarean section (type 3/type 2b). in this study all pro
recombinate- antihemophilic factor recombinant
baxter healthcare corporation - antihemophilic factor, human recombinant (unii: p89dr4ny54) (antihemophilic factor, human recombinant - unii:p89dr4ny54) - antihemophilic factor, human recombinant 25 [iu] in 1 ml - the use of recombinate [antihemophilic factor (recombinant)] is indicated in hemophilia a (classical hemophilia) for the prevention and control of hemorrhagic episodes.2 recombinate is also indicated in the perioperative management of patients with hemophilia a (classical hemophilia). recombinate can be of therapeutic value in patients with acquired factor viii inhibitors not exceeding 10 bethesda units per ml.3 in clinical studies with recombinate, patients with inhibitors who were entered into the previously treated patient trial and those previously untreated children who have developed inhibitor activity on study, showed clinical hemostatic response when the titer of inhibitor was less than 10 bethesda units per ml. however, in such uses, the dosage of recombinate should be controlled by frequent laboratory determinations of circulating factor viii levels as well as the clinical status of the patient. recombinate is not indicated in von willebrand’s disease. recombinate is contraindicated in patients w
haemate p 500iu vial international unit pdr+solv for soln for inj
csl behring gmbh - factor viii (antihaemophilic factor) von willebrand factor - pdr+solv for soln for inj - 500iu vial international unit
haemate p 1000iu via international unit solution for infusion
csl behring gmbh - factor viii (antihaemophilic factor) von willebrand factor - solution for infusion - 1000iu via international unit